# CLAIMS

1. Use of a Galectin-9 agonist in the manufacture of a medicament for treating or preventing a disease, disorder or condition in a mammal, wherein:

   the Galectin-9 agonist promotes or enhances immunity by activating or stimulating Galectin 9 activity;

   the Galectin-9 agonist is multimeric, soluble PD-L2 comprising at least 3 PD-L2 monomers; and

   the disease, disorder or condition is cancer and/or a disease, disorder or condition caused by a pathogen, and is responsive to activating or stimulating Galectin-9.
2. The use of claim 1, wherein the multimeric, soluble PD-L2 comprises 3, 4, 5, 6, 7 or 8 PD-L2 monomers.
3. The use of claim 1 or 2, wherein the multimeric, soluble PD-L2 comprises 8 PD-L2 monomers.
4. The use of any one of claims 1-3, wherein the mammal is a human.